1. Introduction {#sec1}
===============

The word dietary fiber (DF), denoting undigestible extremely intricate carbohydrates and lignins, was first described by Eben Hipsley in his article after seeing people consuming diets high in fiber-rich foods ([@bib45]). In a more elaborated way, DFs comprises a large group of carbohydrates having varied physiochemical characteristics and therefore, also include both fructo and galacto oligosaccharides ([@bib66]). Generally DFs are categorized into two classes i.e as soluble DFs (SDFs) including inulin or beta-glucan, and insoluble DFs (ISDFs) such as cellulose which is a structural carbohydrate not used for energy but mostly constitutes cell wall materials in plant cells ([@bib99]). Whether SDFs or ISDFs, both these kinds of DFs have a range of anticipated functions. For example, due to their partial fermentation which provides bulk to the luminal materials and boost off colonic transit time, ISDFs play a critical role in safeguarding colonic epithelium from the harmful effects of different carcinogenic compounds ingested to the body ([@bib68]).

It is presumed that human gastrointestinal tract (GIT) is home to about 10^14^ bacterial cells, with the most populated and diversified community residing in the large intestine or colon. The presence of these bacterial colonies in the gut has been known to put forward a potential impact on human health. And it could be due to their capability to readily ferment the SDFs into short chain fatty acids (SCFAs), mainly including acetate, propionate and butyrate, as well as other metabolites which in turn confer potential health benefits ([@bib64]). Also, these colonic bacteria are known to have strong influences on metabolic processes and modulation of the immune system and provide significant protection against different pathogenic organisms while modulating GIT growth and development (Sugihara, Morhardt, & Kamada, 2019). The SDFs are also known to enhance bioavailability of beneficial natural flavonoids such quercetins ([@bib125]).

Previous literature shows that DFs have significant beneficial roles in the control of chronic diseases e.g cancer, type 2 diabetes, obesity, cardiovascular diseases (CVDs) etc, which is particularly linked to their impact on the gut microbiota ([@bib115]; [@bib118]). If left untreated, the aforementioned conditions could significantly subsidize in the progression of many life threatening chronic diseases including cancer, insulin resistance, type 2 diabetes and CVD, pro-inflammatory activity, inflammatory bowel disease (IBD) etc ([@bib141]). It is generally believed that the bacterial flora residing in the GIT vary from to person to person, however, mainly it remains stable over time periods ([@bib105]). In this perspective, a range of factors have been known to influence this useful bacterial flora in our GIT. These predominantly include genetical background of the individuals, their physiology, and surrounding environmental factors like living conditions and use of different medications ([Fig. 1](#fig1){ref-type="fig"} ). Nevertheless, among these factors, diet is regarded as the most important environmental factor known to arbitrate their composition as well as other metabolic activities ([@bib38]). Furthermore, in recent decades, DFs have attracted considerable attentions owing to their significant roles being "prebiotics". Prebiotics a group of DFs and are defined as "selectively fermented complex ingredients/carbohydrates that cause and promote specific changes, in the structure and/or function of the GIT bacterial flora, thereby exerting potential health benefit(s) upon host health." ([@bib30]). Being food for probiotics, these prebiotics in combination with probiotics have shown significant antiviral efficacy. For example, in children with acute RotaVirus (RV) gastroenteritis, the oral administration of a mixture of *Bifidobacterium lactis B94* and inulin as prebiotic showed a shorter duration of RV acute watery diarrhea ([@bib50]). Also, milk fermented with *B. breve C50, Streptococcus thermophilus 065*, and combined with prebiotics prevents RV-induced diarrhea when fed to suckling rats ([@bib103]).Fig. 1Key factors influencing the composition as well as metabolic activities of gut microbiota.Fig. 1

In light of the potential health benefits of prebiotics & probiotic given in [Fig. 2](#fig2){ref-type="fig"} , the main aim of the current review is to highlight the importance of DFs in human health with presenting a critical background on its role as prebiotics.Fig. 2Roles and potential health benefits of prebiotics & probiotics.Fig. 2

1.1. Effects of DFs in control of chronic diseases {#sec1.1}
--------------------------------------------------

As stated earlier, diets with high fiber contents are asserted to present significant protective effects against chronic diseases such as metabolic syndrome including type 2 diabetes (M. [@bib86]), CVD and obesity (M. [@bib86]). Substantial research has been carried out so far stating DFs as important formulation in the control and treatment of these pathologies ([@bib99]). In this context, in our previous review we also presented the health benefits of DFs particularly konjac glucomannan (KGM) with critical focus on its role in control of diabetes ([@bib111]). It is thought that the benefit of DFs in control of diabetes is connected with their fermentation by gut microbiota to short chain fatty acids (SCFAs), the deficiency of which may lead to the development and progression of the disease (L. [@bib149]). Although most of the research community assumes that the detailed mood of actions of DFs in safeguarding against these pathologies is up to some extent complicated and not fully known, still there are evidences describing the presence of β-glucans in some DFs (e.g*.*oats) linked to curb the levels of total cholesterol and low density lipoprotein (LDL) cholesterol ([@bib66]). In particular instance, SDFs being more viscous are known to control and lower postprandial blood cholesterol and sugar rises by influencing their absorption from the small intestine because of the formation of gels by these fibers ([@bib76]). Similarly, another mechanism in lowering blood cholesterol levels by SDFs involve their capability to attenuate the quantity of bile reabsorbed in the intestines thereby elevating the excretion of bile in feces ([@bib123]). And in order to cope with this loss, the liver stimulates the release of extra bile salts via enhancing the production of LDL cholesterol receptors, which skillfully perform separation of LDL molecules in the blood stream ([@bib55]). Consequently, the elevated bile salts production by the liver causes isolation of more LDL molecules from the blood. Furthermore, in another way SDFs and indigestible starch molecules go through fermentation by intestinal bacterial flora resulting in the productions of SCFAs, which in turn aid in attenuating circulating cholesterol levels in blood ([@bib123]).

No doubt while speaking about CVD, the term "obesity" can\'t be ignored as it is one of the main reasons for CVD related morbidities and mortalities. Till date, a substantial amount of research work has been reported dealing with interventional human trials to determine the potential effects of DFs rich diets or DFs supplements in weight loss management. The reason could be the indigestible characteristic of DFs which prolong their transit time in the intestinal lumen and thereby induce greater satiety compared with simple and digestible polysaccharides which are readily digested. Furthermore, DFs could also be involved in prolongation of meal intervals and induce an enhanced mastication with presumable cephalic and peripheral effects on satiety. Interestingly and more healthfully diets rich in DFs have a lesser energy bulk and could influence palatability of foods, which could ultimately lead to a lower calories intake ([@bib9]). Another mechanism related to appetite reducing effects of DFs, is based on stimulating the signaling of GIT satiation peptide hormones such as glucagon-like peptide (GLP-1) and peptide YY (PYY) or glucose dependent insulinotropic peptide (GIP) by DFs which result from their fermentation in the large intestine by gut microbiota ([@bib71]). [@bib43] found that both oat and wheat fiber significantly reduced body and adipose tissues weight in the rats fed with high fat diet (HFD). Also compared to HFD group, cereal DFs increased protein expressions involved in the lipolysis and browning process. From their results, they concluded that cereal DFs promoted adipocyte lipolysis by the cAMP--PKA--HSL pathway and enhanced WAT browning by activation of UCP1, and consequently reduced visceral fat mass in response to HFD feeding ([@bib43]). It is crucial to mention here that although research studies conducted on animal experimental models usually have more pronounced effects, however, the amount of fibers generally used in these studies are also higher compared to the levels used in human clinical trials, particularly in cases for prebiotics, where the dose is generally 40-fold higher on the basis of body weight ([@bib77]).

The preceding results imply that DFs have shown significant effects in control and treatment of different pathological conditions, still there are reports where contradictory results have been observed in the treatment groups in comparison to the control ones. For example, in a study conducted to evaluate the effects of fibers intake on inflammatory markers (IM) in post-menopausal women, it was found that women in the higher fibers intake group (24.7 g/day) had lower plasma IL-6 and TNF-α-R2 (receptor 2 of the TNF-α) levels as compared to those with lower ingestion (7.7 g/day). However, there was no association between fibers and c-reactive protein (CRP) in both the groups ([@bib40]). Likewise, in another study individuals from different ethnical groups, who consumed more fibers (1.39 g/serving of food) compared to those with the less consumption (0.02 g/serving) were favored with lower CRP values ([@bib62]). Even higher intake of DFs (43.8 g/day) as compared to lower intake (8.2 g/day) didn\'t show significant effects on IM in the two experimental groups, except for the lower values of homocysteine among several individuals analyzed in the study. And hence, the authors of the study concluded that there could be many influential factors such as group homogeneity, better conditions of the subjects assessed to get fiber-rich diets, statistical errors in the measures of randomization, that affected outcomes of the study ([@bib54]). As human trials with consumption of DFs dosage greater than 50 g/day exhibited significant improvements in the assessed health markers (S. J. [@bib92]; L. [@bib149]), it could be postulated that the health benefits of DFs are strongly co-related with their daily intake and it is suggested to be greater than 50 g, which could be achieved not only by regular food but also with the addition of supplements (S. J. D. [@bib91]). However, in modern world there could be problems in tolerating such a higher dose and could lead to a number of gut related undesirable conditions like flatulence, bloating, stomach pain, diarrhea, and constipation ([@bib37]).

1.2. Colonic microflora and fermentation of DFs {#sec1.2}
-----------------------------------------------

As stated earlier, the human gut is a natural habitat for trillion of microorganisms which not only contribute a significant role in promoting GIT health itself but also play their potential part in general health well beings. The diversity and constitution of bacterial flora residing in the GIT significantly differ from person to person and is greatly affected by many factors including age ([@bib78]), genetics ([@bib58]) and Neolithic settlements ([@bib69]). However, among them, dietary habits are regarded as one of the most crucial factors which can be modified accordingly by selecting the diets rich in complex undigestible components (resistant starches), unable to be digested by human enzymes but rather by these bacteria for their growth and energy ([@bib82]). As schematically shown in [Fig. 3](#fig3){ref-type="fig"} , these undigested complex and resistant starches arriving the colon of large intestine encounter anaerobic fermentation producing vital SCFAs (mainly acetate, propionate and butyrate) ([@bib15]). Broadly speaking, each of the produced SCFAs has a different and individual role in exerting healthy effects but in general they perform a fundamental collective role. For example being weak acids, all of the produced SCFAs cause in decreasing the colonic pH which is of potential advantage to prohibit the growth of harmful pathogenic bacteria such as *Enterobacteraciae* due to their sensitivity to low pH ([@bib10]). More specifically, on individual scale, it has been researched that after being transported to liver, propionate efficiently contribute in gluconeogenesis to produce glucose from non-carbohydrate sources (i.e. proteins or lipids). Similarly, acetate is carried in the blood to the peripheral tissues, where it is involved in enhancing ATPs production via citric acid cycle thereby scaling up fermentation proficiency ([@bib35]). On the other hand, butyrate is known as an important calorie source for the colonic epithelial cells instead of other energy sources like glucose and glutamine. Butyrate is thought to be a fundamental nutrient executing the metabolic activity and growth of colonocytes and may work as a prime safeguarding factor against colonic disturbances ([@bib88]). These claims were further backed by the results stating a significant reduction in butyrate-producing bacteria in feces of individuals suffering from ulcerative colitis and colon cancers in comparison to the healthy subjects ([@bib114]; L.; [@bib149]). Also, butyrate has shown the capability of promoting metabolic disorders (CVD and related disorders) via seral mechanisms including AMPK activation and GLUT4 expression in the adipose tissue, combating high fat diet (HFD) incited gut microbiome dysbiosis, and stimulating resolvin E1 and lipoxin biosynthesis ([@bib29]). Its noteworthy to mention that the roles and actions of SCFAs are also highly controversial. And it has been known that in mice, SCFAs usually evoke positive effects on disease phenotype but in humans, this effect is not as straightforward ([@bib17]). Also, SCFA turnover is very high and local, hence measures of SCFA in plasma/feces should be interpreted with great caution since it is unlikely to be an accurate representation of SCFAs metabolism ([@bib129]).Fig. 3Interplay between dietary fiber and colonic microbiome.Fig. 3

1.3. Effects of DFs on composition of gut microbiome {#sec1.3}
----------------------------------------------------

Previous literature has acknowledged that the kind of dietary substrate as well as the overall DFs in the diet are the two factors that potentially affect the composition of gut microbiota. Consequently, this alteration in bacterial composition in the gut by DFS in turn influences several important processes such as pH and amounts of SCFAs, which can ultimately even have a strong impact on the bacterial composition itself. This provided scientists around the world with an interesting background to identify and comprehensively understand the relationship between different kinds of DFs and the gut microbiota. One research group analyzed and compared the fecal bacterial contents of children from two different ethnic groups i.e European children (EU) and children from a rural African village of Burkina Faso (BF), which is the area where the diet is generally believed to contain higher amounts of fibers, as occurred during the early human settlements from the time when agriculture came into being. They found significant differences in the gut microbiota of the two selected groups as analyzed by high-throughput 16S rDNA sequencing and biochemical analyses. Furthermore, they also determined a significant difference in the production of short-chain fatty acids (P \< 0.001) in BF than in EU children ([@bib22]). Another research group described the same phenomenon by determining the effects of a highly branched randomly linked polysaccharide i.e Polydextrose, and a SDF derived from corn containing oligosaccharides with random glycosyl bonds. Performing 454 pyrosequencing, these fibers exhibited a favorable move in the gut microbiota of the adult population thereby hallmarking them with potential application as prebiotics ([@bib48]). Inulin a potential DF based prebiotic is a carbohydrate formed by β-D (2 → 1) linked fructose oligomers with terminal β-D fructose or α-D glucose units joined by α-D (1 → 2) linkage which has gained tremendous attention in functional foods development ([@bib3]; J.; [@bib134]). On large industrial scale, inulin obtained from dahlia, chicory and Jerusalem artichoke and is well known prebiotic having astonishing beneficial characteristics which made it interesting candidate to be extensively used in formulating functional foods ([@bib136]). It has shown to aid in the prevention of diarrhea associated with enteral nutrition and to boost up GIT health ([@bib26]; [@bib113]), to enhance stability and protection of probiotics ([@bib67]; [@bib95]), to reduce fat contents of the food products ([@bib31]) etc. The principal product obtained by inulin fermentation is butyrate, which is thought to be the result of two different mechanisms. The first pathway involves the condensation of two molecules of acetyl coenzyme A and the reduction of them to butyryl-CoA. In the other connected metabolic pathway, the generated butyryl-CoA:acetate CoA transferase can move the CoA to extrinsic acetate, resulting in the production of butyrate and acetyl-CoA ([@bib56]). In earlier times Hannah et al. determined the influence of agave inulin on gut microbiome. Agave inulin, which is consisted of linear and branched fructose chains, connected with β-2,1 and β −2,6 linkages, is considered different from other inulin kinds of fibers both in chemical composition as well as botanical origin. After feeding to healthy individuals with different doses in a randomized, double-blind, placebo-controlled, 3-period, crossover trial, it was concluded that agave inulin supplementation significantly altered the GIT microbiota composition and activity in the selected healthy individuals ([@bib47]). In the next year, Birgitte and colleagues., evaluated the effects of dietary inulin, cellulose or brewers spent grain (BSG) on intestinal tumorigenesis and cecal microbiota. Their results demonstrated that the type of DF contributes a potential role in the progression of colorectal cancer; however the protective effects of dietary inulin against colonic tumorigenesis is strongly linked with the profound alterations in the ceacal microbiota profile ([@bib85]). Nevertheless, the impact of different dietary trials in clinical practice have shown controversial results due to a significant variability in individual response against the tested diet, which could be linked to variations in their gut microbiome as stated earlier that gut microbiome vary from person to person. Last year Biesiekierski and colleagues published a comprehensive review on these issues by citing studies dealing with the predictive dimensions of baseline microbiome for clinical response to dietary trials in two particular pathological conditions, i.e. obesity and IBS ([@bib11]). Therefore, it is still a challenging task and needs further large-scale interventions to address and provide solid grounds for these claims that can be significantly undertaken in clinical practices.

1.4. Whole grains and gut microbiome {#sec1.4}
------------------------------------

According to AACCI, the whole grains (WGs) can be defined as the "integral, ground, cracked or flaked fruit of the grain whose original three parts, the starchy endosperm, germ and bran, are present in the same relative proportions as they exist in the intact grain" ([@bib1]). Generally speaking, the WGs constitute a huge group of staple foods that includes wheat, corn, rice, oats, barley, rye and so on ([@bib49]). It is evident from the available literature that WGs confer a broad spectrum of potential health benefits due to their richness in bioactive compounds which may significantly affect processes like energy metabolism, weight regulation and food intake ([@bib63]). One possible mechanism by which WGs confer benefits maybe be associated with their capability of modulation gut microbiota where DFs are regarded as the fundamental factor to stimulate this modulation. It is postulated that the fiber contents of the WGs imparts enhanced viscosity to the digesta and lower glucose as well as cholesterol levels by binding to the bile acids in the small intestine ([@bib133]), thereby implying DFs and whole grains based diets very important in diabetes management to aid in glycaemic, cholestrol as well as body weight, and inflammation controls ([@bib102]; [@bib131]). Similarly, another pivotal role of WGs involve their ability to curb protein fermentation by the gut microbiota, which can ultimately lead to protein fermentation accountable for unwanted fermentation metabolites and harmful impacts on the host ([@bib107]). Also, another noteworthy characteristic of the WGs is their richness in resistant starch (RS) which is particularly butyrogenic and thus scale up the increased production of butyrate by the bacterial fermentation ([@bib33]). And the bacterial fermentation of the undigestible components of WGs in the GIT has been agreed upon to be partly associated with the healthful effects of WGs ([@bib63]). In addition, the WGs have also demonstrated an anti-inflammatory activity and hence can be of significant benefit in lessening of metabolic inflammation responsible for metabolic disorders ([@bib81]) as has been mentioned in a meta-analysis of 9 randomized trials ([@bib137]). This specific significance of WGs become particularly applicable in light of recent research that designated a strong connection of gut bacteria involvement in metabolic disorders ([@bib39]). Therefore, in 2013, a research group evaluated the influence of the diet supplemented with WGs on gut microbiota in healthy human subjects. They also explored a possible connection between metabolic and immunological advancements observed in response to the experimental diet. Their results stated that short-term utilization of the WGs significantly modified the composition of the gut microbiota which as a consequence interestingly supported in excelling host physiological actions connected with metabolic dysfunctions in humans ([@bib80]). In the year 2017, Sally and his research group evaluated the effects of two different types of diets 1) rich in WGs and 2) rich in refined grains (RGs) on immune and inflammatory responses, gut microbiota, and microbial products in healthy adults while maintaining subject body weights. Presenting their results, they stated that the short-term consumption of WGs had significant effect on the studied parameters in comparison to the RGs diets. The WGs maintenance diet increased stool weight and frequency and had modest positive impacts on gut microbiota, SCFAs, effector memory T cells, and the acute innate immune response and no effect on other markers of cell-mediated immunity or systemic and gut inflammation ([@bib128]). In the following year, researchers from Japan in a randomized double-blind study investigated the effects of WGs wheat bread on visceral fat obesity in Japanese individuals. After 12 weeks of experimental trials, the subjects who consumed WG wheat bread showed significant and safe reductions in visceral fat areas ([@bib61]). Similar phenomenon was also described by another group in a randomized control showing the role of WGs to promote gastrointestinal health in overweight and obese individuals ([@bib65]). In the following year, the effects of dietary WG, fruit, and vegetables on weight and inflammatory biomarkers in 75 overweight and obese women were assessed in a randomized control trial. Significant modifications in serum biomarkers (CRP, TNF-α, IL-6, D-dimer, and serum fibrinogen) after consuming the trial diet for 10 weeks suggested WG based diet to support in attenuating inflammatory degrees and control following unpleasant health outcomes ([@bib5], pp. 1--9). WG millet has also shown significant impact on lipid metabolism in both the in vitro cells and the in vivo rats (fed with high fat diet) experimental models. Associated with its lowering lipid storage, total cholesterol and triglyceride contents in the cells, it was found that WG millet exhibit hypolipidemic characteristics by modulating lipid metabolism concomitant genes expression or composition of gut microflora ([@bib72]). However, in the same year another research group found that whole barley had the potential in preventing obesity and dyslipidemia in germ free C57BL/6J obese mice with or without the involvement of gut microbiota related mechanisms ([@bib34]). These observations were further supported by another randomized cross-over trial stating body weight and systemic low-grade inflammation lowering effects of WG without major modifications in the composition of gut microbiota ([@bib104]; [@bib133]). Nevertheless, most recently, Zhu and colleagues found that a fiber rich Med diet changed human gut microbiota composition and its metabolites after consumption of just 4 days in comparison to an animal fat--rich, low-fiber fast food diet ([@bib150]). The preceding discussion hallmarks a wide range of health benefits conferred by different WGs. In order to elucidate the extent to which WGs offer these healthy impacts, Hui et al. categorized the lipid monitoring effects of different WGs by performing a network meta-analysis of fifty-five studies including a total of 3900 participants. They found oat bran to be the most effective than barley, brown rice, wheat and wheat bran which were not reported with significant effects on blood lipid profiles ([@bib49]). Moreover, the efficacy of WGs in prevention of cancer has also been extensively research previously. In this perspective, in the cancer prevention study-II nutrition cohort, it has been found that higher WGs intake was linked with lower incidence of colorectal cancer risks in older US men ([@bib126]) and gastric cancer risks as summarized in a meta-analysis of observational data from a registered study (Y. [@bib138]).

1.5. Prebiotic effects of DFs {#sec1.5}
-----------------------------

Prebiotics are known as the "selectively fermented food ingredients that allow particular modifications both in the composition and/or performance of the gut microflora, thereby imparting health benefits to the host" ([@bib30]). This definition elaborates that not all DFs can be put together in the group of prebiotics; however, most of the prebiotics can be regarded as DFs ([@bib115]). Scientifically, food constituents can be classified as prebiotics if they proficiently perform these actions; (i) must resist gastric acidity, hydrolysis by human enzymes, and gastrointestinal absorption; (ii) must be fermented by the gut microflora; (iii) must stimulate the growth and activity of gut microflora associated with health ([@bib21]). Till date a substantial research has stamped prebiotics as important formulations contributing to the well-being of human health. For example, they have been claimed to promote gut epithelial barrier concerns, prevent apoptosis of intestinal epithelial cells, and attenuate intestinal inflammation and carcinogenesis ([@bib6]). Similarly, prebiotics were also found to lower down obesity in experimental obese mice by affecting the gene expression style occurring in their white adipose tissues, and therefore resulting in increasing lipolysis, a decreased adipogenesis and elevated metabolic response to leptin (E. M. [@bib24]). Furthermore, prebiotics potentially contribute in ameliorating metabolic disorders e.g. type 2 diabetes and CVD via promoting and stimulating gut microbiota, which in turn stimulates insulin-signaling and cholesterol-lowering characteristics ([@bib141]). It is believed that the suggested pathways could comprise the secretion of gut peptides with incretin role, such as glucagon-like peptide 1, which takes part in the development of hepatic insulin resistance (T. D. [@bib87]). Prebiotics have also exhibited shielding effects on liver, because of their capability to prevent the hepatic storage of TAG and/or cholesterol in the liver tissue known as steatosis ([@bib73]).

In light of the preceding discussion, it can be stated that consumption of prebiotics in addition to DFs is considered as an avenue in the modulation of gut microbiota. The natural sources of prebiotics with their ample quantities include foods such as asparagus, leeks, garlic, onion, Jerusalem artichokes, oats and soybeans so on ([@bib21]). Popular prebiotics, such as lactulose, galacto oligosaccharides and inulin-type fructans (eg, inulin, oligofructose and fructo-oligosaccharides), have been shown to perform a critical role in stimulating beneficial alternation in the gut microbiota composition as well as function including SCFAs production and modulating appetite and satiety) ([@bib12]). Earlier studies have recognized the reality that oligosaccharides, particularly fructo oligosaccharides (FOS) and inulin are key candidates acknowledged for their prebiotic roles. Outcomes of randomized control trials have revealed that these oligosaccharides enhance production of *Bifidobacterium* (a genus of oligosaccharides fermenting gut microflora) as well as *Lactobacillus* species ([@bib124]). Nevertheless, lately some other bacterial species such as *Roseburia intestinalis*, *Ruminococcus bromii* and *Faecalibacterium prausnitzii* are evolving as bacteria linked with good health ([@bib20]). This assures that prebiotic treatment is not involved just in boosting *Bifidobacterium*, but also endorses other species displaying anti-inflammatory characteristics (*Faecalibacterium prausnitzii)* and weight control *(Akkermansia muciniphila)* ([@bib147]). This claim was further supported by the findings of Dewulf et al. presenting human subjects. They issued their results with a statement that even though the rise in *Bifidobacteria* remains the foremost and common signature of the prebiotic approach, a complex modulation of the gut microbial ecology also happens upon prebiotic treatment in obese individuals (E. [@bib23]). A summary of clinical trials based on pre & probiotics applications conducted in aim to treat different diseases during the past decade mostly during the last five years has been outlined in [Table 1](#tbl1){ref-type="table"} .Table 1Summary of clinical trials based on applications of prebiotics and probiotics aimed for the treatments of different diseases.Table 1S. NoStudy designName of diseaseNo. of patientsAge group (in years)Duration of the studyName of pre & prebiotic usedControl groupMain outcome of the studyReferences1Randomized Control Trial (RCT)Irritable bowel syndrome (IBS)3919--754 weeks*Lactobacillus acidophilus, L. rhamnosus, Bifidobacterium breve, B. actis, B. longum, and Streptococcus thermophilus*PlaceboSignificantly enhanced the fecal contents of most probiotic strains.\
Promoted diarrhea-symptom scores in the IBS patients.[@bib142]2Double Blind Clinical TrialInflammatory bowel disease (IBD)10536--388 weeks*Lactobacillus acidophilus La-5 and Bifidobacterium BB-12*PlaceboSignificantly increased the numbers of *Lactobacillus, Bifidobacterium, and Bacteroides* in the treated group[@bib110]3Randomized, Double-Blind, Placebo-Controlled TrialInfantile colic24\<1 (3 weeks-6 months)21 days*Lactobacillus reuteri DSM 17938*PlaceboSignificantly improved colic symptoms[@bib18]4RCTNecrotizing enterocolitis (NEC)400\<1 (\<32 weeks)8 weeks*Bifidobacteriumlactis* as probiotic and inulin as prebioticPlaceboProbiotic (*Bifidobacterium lactis)* and synbiotic (*Bifidobacterium lactis* plus inulin) but not prebiotic (inulin) alone decrease NEC[@bib25]5RCTNonalcoholic fatty liver disease (NAFLD)4218--658 weeks*Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum, Streptococcus thermophilus*PlaceboSignificantly reduced insulin, insulin resistance, TNF-a, and IL-6 decreased[@bib108]6RCTRheumatoid arthritis (RA)4620--808 weeks*Lactobacillus casei 01*PlaceboNo significant effect on oxidative status was observed between the treated and placebo groups[@bib127]7Randomized, Double-Blind,\
Placebo-Controlled TrialRA3025--708 weeks*Lactobacillus acidophilus,*\
*Lactobacillus casei, Bifidobacterium bifidum*PlaceboSignificantly improved Disease Activity Score of 28 Joints (DAS-28).\
Significantly lowered serum insulin levels, homeostatic model assessment-B cell function (HOMA-B), and serum high-sensitivity C-reactive protein (hs-CRP) concentrations[@bib144]8Randomized, Double-Blind,\
Placebo-Controlled TrialAlzheimer\'s Disease (AD)6060--9512 weeks*Lactobacillusacidophilus, Lactobacilluscasei,Bifidobacteriumbifidum, andLactobacillusfermentum*PlaceboSignificantly improved Mini-mental state examination (MMSE)score in the treated group.\
No considerable effect on oxidative stress and inflammation, fasting plasma glucose, and other lipid profiles was observed[@bib2]9Randomized, Double-Blind,\
Placebo-Controlled TrialParkinson disease (PD)12071.8 ± 7.74 weeks*Streptococcus salivarius subsp thermophilus, Enterococcus faecium, Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus plantarum,*\
*Lactobacillus paracasei, Lactobacillus delbrueckii subsp bulgaricus, and Bifidobacterium* as probiotics and Psyllium fiber as prebioticPlaceboSignificantly improved constipation in PD patients.[@bib7]10Randomized, Double-Blind, Placebo-Controlled TrialOverweight diabetic patients with coronary heart disease (CHD).3040--8512 weeks*Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum,* as probiotics and Inulin as prebioticPlaceboSignificantly decreased plasma glucose, serum insulin concentrations.\
Improved insulin sensitivity.[@bib122]11Double-Blind, Placebo-Controlled TrialIBS5418--708 weeks*Lactobacillus rhamnosus*\
*L. casei, L. paracasei, L. plantarum L. acidophilus, Bifidobacterium bifidum, B. longum, B. breve, B. infantis, Streptococcus thermophilus, L. bulgaricus and Lactococcus lactis*PlaceboNo significant difference was observed between the treated and placebo groups[@bib46]12Randomized Triple-Blind\
Placebo-Controlled TrialNAFLD6410--1812 weeks*Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus*PlaceboSignificantly decreased levels of alanine aminotransferase, mean aspartate aminotransferase, mean cholesterol, low-density lipoprotein-C, and triglycerides as well as waist circumference in the intervention group.\
No significant change in weight, body mass index, and body mass index z score was observed between the two groups.[@bib27]13Double-Blind, Placebo-Controlled TrialOverweight or obesity227--1212 weeksOligofructose-enriched inulinPlaceboSignificantly decreased body weight z-score, percent body fat, and percent trunk fat and levels of interleukin 6 and serum triglycerides in the treated group.[@bib89]14Randomized, Double-Blind, Placebo-Controlled TrialIBS2230--5010 weeks*Bifidobacterium longum NCC3001 (BL)*Placebo*BL* reduced depression but not anxiety scores and increases quality of life in patients with IBS[@bib96]15Randomized Double-Blind Placebo-Controlled Clinical TrialDiabetes6054.0 ± 16.012 weeks*Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum*PlaceboSignificantly decreased fasting plasma glucose, homeostasis model of assessment-estimated insulin resistance, homeostasis model of assessment-estimated beta-cell function and HbA1c, and improved quantitative insulin sensitivity check index.\
Significantly reduced serum high-sensitivity C-reactive protein, plasma malondialdehyde, subjective global assessment scores and total iron binding capacity, and a significant increase in plasma total antioxidant capacity[@bib117]16Randomized, Double-Blind TrialOverweight or obesity2120--598 weeks*Lactobacillus acidophilus and casei; Lactococcus lactis; Bifidobacterium bifidum and lactis*PlaceboSignificantly reduced the waist circumference, waist-height ratio, conicity index, and plasma polyunsaturated fatty acids and increased the activity of glutathione peroxidase.[@bib32]17Double Blind Randomized Clinical TrialNAFLD7520--6012 weeks*Bifidobacterium longum (BL) and Lactobacillus acidophilus* as probiotic and inulin high performance (HP) as prebioticPlaceboSupplementation with probiotics and/or prebiotics improved amino transferase enzymes, and supplementation with probiotics or pro- and prebiotics recovered the grade of fatty liver in NAFLD patients.[@bib51]18Randomized, Double-Blind, Placebo-Controlled TrialOverweight and obese type-2 diabetes6030--5545 daysSodium butyrate and inulinPlaceboSignificantly improved *Akkermansia muciniphila* percent change.\
Significant decreased TNF-α mRNA, hs-CRP, MDA and diastolic blood pressure levels in the treated groups[@bib106]19Randomized Controlled Clinical TrialDiabetic kidney disease (DKD)4832--688 weeks*L plantarum A7*PlaceboImproved oxidative stress factors among DKD patients[@bib83]20Double Blind Randomized Clinical TrialNAFLD8420--6012 weeks*BL* as probiotic and inulin as prebioticPlaceboProbiotic and prebiotic supplementation improved serum lipid profile and insulin resistance markers in NAFLD patients.[@bib52]21Placebo-Controlled,\
Double-Blind Randomized Controlled TrialMajor depressive disorder8118--508 weeks*Lactobacillus helveticus* and *B.L.* as probiotic and galactooligosaccharide as prebioticPlaceboImproved Beck Depression Inventory (BDI) score in the treatment group[@bib57]22Single-Blind, Parallel, Randomized, Placebo-Controlled TrialOverweight or obesity4130--6512 weeks*Bacillus coagulans BC30, 6086 as probiotic and β-glucans as prebiotic*PlaceboThe formulated synbiotic pasta showed synbiotic exhibited beneficial effects on plasma resistin, plasma LDL/HDL cholesterol ratio, and plasma hs-CRP[@bib4]23Double-Blind, Placebo-Controlled, Randomized Clinical TrialOverweight or obesity5020--6012 weeks*B. breve* CBT\
BR3, *L. plantarum CBT LP3* as probiotic and fructo-oligosaccharide as prebioticPlaceboSignificantly improved obesity-related markers in obese people[@bib119]

1.6. Anti-viral efficacy of prebiotics & probiotics {#sec1.6}
---------------------------------------------------

Nowadays a strong and efficient inner defense mechanism (immunity) is more and more important than ever before. In this perspective, balanced nutrition and wise selection of nutrients can be a crucial strategy to significantly aid in excelling our immune system. These facts are backed by different research works which have shown that prebiotics and probiotics modulate the gut microbiota and interact with innate and adaptive immunity. This could be due to the existence of the major part of immune systems in the large intestine which is home to trillions of beneficial micro-organisms (microbiome) ([@bib132]). A substantial research work has been done in this area to provide scientific proofs for these claims. For example, in a randomized placebo-control trial, it was hypothesized that early prebiotic or probiotic supplementation would reduce the risk of virus-associated respiratory tract infections (RTIs) during the first year of life in a cohort of preterm infants. The results concluded that supplementation with prebiotics galacto oligosaccharide and polydextrose mixture at ratio1:1 and a probiotic (*Lactobacillus rhamnosus* GG, ATCC 53103) significantly reduced the incidence of (RTIs) in these children as compared to the control placebo group receiving (microcrystalline cellulose). And hence it was suggested that gut microbiota modification with specific prebiotics and probiotics might offer a novel and cost-effective means to reduce the risk of rhinovirus infections ([@bib75]). The same probiotic bacterium (*Lactobacillus rhamnosus*) also showed to enhance macrophage viability for HSV-1 (herpes simplex virus type 1) elimination and activation against HSV-1 more effectively than non-probiotic *Escherichia coli* ([@bib59]). Another study determined the anti-influenza virus effects of both live and non-live *Lactobacillus acidophilus* L-92 accompanied by the activation of innate immunity. The results concluded potential protective effects of the orally administrated (10 mg/mouse per d) probiotics bacteria against influenza virus infection in mouse model infected intranasally with influenza virus (H1N1) ([@bib36]). Rotavirus (RV) infection, the underlying cause of diarrhea and vomiting leads to sever dehydration in patients specially children and therefore is consider the second leading cause of mortality in children \< 5 years of age ([@bib140]). One of the possible biological pathways inducing diarrhea due to the infection is nonstructural protein (NSP4) production that causes Ca^2+^ -dependent transepithelial secretion. Therefore, the antiviral activity of four probiotic metabolites (*Lactobacillus casei* and *Bifidobacterium* species) was evaluated using in vitro RV infection model. The findings demonstrated that probiotic metabolites were capable to interfere with the final amount of intracellular NSP4 protein and a successful Ca^2+^ regulation, thereby suggesting probiotics based novel approach against the RV infection ([@bib93]). In 2017, researchers from China evaluated the effects of probiotic bacteria *Lactobacillus plantarum* strain N4(Lp) against transmissible gastroenteritis coronavirus. The results found a significant viral yields reduction in the treatment groups due to the optimal inhibition of viral RNA replication ([@bib139]). Last year in another randomized, placebo-controlled trial with 258 healthy children aged 3--6 years consuming 6 g/day prebiotic inulin-type fructans or maltodextrina, it was found that supplementing these children during a cold season with the prebiotic significantly reduced febrile episodes requiring medical attention and lowered the incidence of sinusitis, which could be attributed to the modulation of specific gut microbiota by this prebiotic ([@bib116]). In the same year, another research group evaluated the in vitro immunomodulatory and anti- *Campylobacter jejuni* activities of probiotic *lactobacilli* spp*. (L. salivarius, L. johnsonii, L. reuteri, L. crispatus, and L. gasseri).* The results demonstrated that *lactobacilli* carry differential antagonistic effects against *C. jejuni* and vary in their ability to trigger off innate responses ([@bib121]).

1.7. Prebiotics and probiotics based formulations (emulsions & nano, microparticles) {#sec1.7}
------------------------------------------------------------------------------------

In recent years a greater attention has been attracted by different kinds of prebiotic formulations. Among them, nowadays the most favorable and predominantly practiced one is the encapsulation of these prebiotics into emulsions or nano & microparticles based systems (summarized in [Table 2](#tbl2){ref-type="table"} ). Encapsulation is a versatile technique used to enclose the encapsulants within polymeric solid, liquid or semi-solid shells in order to protect them from the harsh environments (e.g light, oxygen, pH, heat etc) as well as to control their release. For example, Vito et al. produced emulsion filled gels (EFG) based on inulin and extra virgin olive oil, by means of both mechanical shearing and ultrasound homogenization ([@bib94]). Similar study was also conducted by another research group which evaluated the stability, consistency, and oil oxidation of emulsion filled gel prepared by inulin and rice bran oil using ultrasonic radiation ([@bib90]). In order to enhance microbiological, nutritional, and sensory quality of strawberry juices after 2 weeks of refrigerated storage, another study group reported the enrichment of the juices with prebiotic fiber (inulin and oligofructose) and their preservation treatment (with ultrasound and geraniol). As a result, combining preservation treatment (geraniol) with prebiotics (inulin and oligofructose) showed to be an efficient strategy to control the native microflora, as well as, to inhibit inoculated pathogens in strawberry juice during 2 weeks of refrigerated storage ([@bib16]). Gum odina (GO~d~) a plant-derived gum, which is non-toxic in nature and is capable of enhancing immune system of the body due to its prebiotic action ([@bib84]). Aditya et al. developed a multiple emulsion (W/O/W) of lamivudine using a GO~d~ to increase bioavailability and patient compliances of the encapsulated drug. GO~d~ was employed to stabilize both the interfaces of liquid membrane in both the external and internal aqueous phases. Their results provided a promising scope for GO~d~ stabilized W/O/W multiple emulsions in antiviral therapies ([@bib53]). Addition of prebiotic ingredients also reduce the health risk of certain foods associated with their high contents of sodium, fats, fatty acid fatty acid profile rich in saturated fatty acids and cholesterol, which can increase the incidence of chronic disease such as coronary heart disease (CVD), obesity, high blood cholesterol and cancer. Within this context Maria et al. evaluated the effect of the addition of various prebiotic fibers on the rheological and technological properties and the microstructure of an emulsified meat product (bologna). They concluded that the simultaneous addition of a partial level of cassava starch and the prebiotic fibers would improve the stability of the meat emulsions, allowing the reliable production of a healthier bologna sausage ([@bib28]).Table 2Summary of recent advancements in prebiotics and probiotics formulationsTable 2S. NoName of prebiotic or probiotic usedFormulationsPotentials of the formulationsReferences1*Lactobacillus gasseri* (L) and *Bifidobacterium bifidum* (B) as probiotics and quercetin as prebioticalginate-chitosan capsulesTo enhance survival of the probiotic bacteria and keeping intact the prebiotic during exposure to the adverse conditions of the GIT[@bib19]2Inulin, FOS, polydextrose, and resistant starchMeat emulsionTo reduce sodium chloride and pork-back-fat contents of the emulsified meat product (bologna)[@bib28]3Probiotic *Bifidobacterium* BB-12 and prebiotics inulin and polydextroseMicrocapsulesTo improve stability of the microcapsules and protect the encapsulated probiotic[@bib97]4InulinEmulsion filled gelsTo reduce fat content in the foods[@bib94]5*Lactobacillus salivarius NRRL B-30514* as probiotic and pectin as prebioticsEmulsionTo enhance viability of the encapsulated probiotic bacteria[@bib145]6InulinEmulsionTo enhance the retention and antioxidant efficacy of geranylgeraniol (bioactive compound)[@bib112]7InulinNanocomplexesProtection and delivery of encapsulated resveratrol and to enhance the prebiotic efficacy of the complexes[@bib42]8InulinMicrocapsulesTo enhance protection and retention of the encapsulated thymol[@bib143]9*Lactobacillus salivarius NRRL B-30514* as probiotic and sugar beet pectin as prebioticsEmulsionTo enhance viability of the encapsulated probiotic bacteria[@bib146]10Potato starch (PS), Plantago psyllium (PSY) and Inulin (IN)) as prebiotics and *Lactobacillus casei Shirota* (Lc) and *Lactobacillus plantarum* (Lp33 and Lp17) as probioticsMicrocapsulesTo protect the encapsulated bacteria and enhance their viability[@bib95]11Lactic acid bacteria as probitioc and cactus pear peel or apple marc flours as prebioticsMicrocapsulesTo protect the encapsulated bacteria and enhance their viability[@bib109]12Inulin (IN), and oligofructose (OL)EmulsionTo enhance storage, release and antioxidant properties of the encapsulated lime essential oil[@bib14]13*Bacillus coagulans* as probitioc and Pectin as prebioticbionanocompositeTo enhance protection of the encapsulated bacteria[@bib60]14*Lactobacillus rhamnosus*EmulsionTo enhance viability of the encapsulated probiotic bacteria[@bib79]15Gum odina (GO)EmulsionTo increase bioavailability and patient compliances of the encapsulated anti-retroviral drug lamivudine[@bib53]16InulinEmulsionTo produce reduced fat mayonnaises[@bib13]17*Escherichia coli* O157:H7 and *Listeria innocua* as probitoics and Inulin and oligofructose as prebioticsStrawberry juicesTo enhance quality parameters (microbiological, antioxidant capacity indicators, and sensory) of the juices and enhance safety and protection of the encapsulants[@bib16]18InulinSoursop flavored whey beverageTo scale up the physical stability of the system[@bib41]19InulinWhey beverageTo scale up kinetic stability of the system[@bib41]20InulinEmulsion filled gelTo enhance stability and consistency of the synthesized system[@bib90]21*Lactobacillus rhamnosus*EmulsionTo obtaining a low-saturated fat ice cream functionalized with probiotic bacteria[@bib13]22InulinEmulsion-filled gelTo produce fermented sausages with reduced fat and improved stability as well as fatty acid composition,[@bib31]23InulinEmulsionTo enhance the stability and thickening of the synthesized system[@bib74]24InulinEmulsionTo enhance the stability and protein digestibility of the formulated enteral formulas[@bib120]25*Lactobacillus acidophilus* as probitoc and rice bran, inulin and hi-maize as prebitoticsAlginate microparticlesTo enhance viability of the encapsulated probiotic bacteria[@bib98]26*Enterococcus faceium* as probiotic and Inulin as prebioticNanoemulsionTo enhance viability and protection of the encapsulated probiotic bacteria[@bib67]27*Saccharomyces boulardii and Enterococcus faecium*EmulsionTo enhance growth and survival of the encapsulated proboiotic bacteria[@bib100]28InulinLiposome and emulsion gelsTo enhance oxidative stability of the synthesized system[@bib70]29octenyl-succinic anhydride (OSA) starch, Inulin (IN), maltodextrin (MD), chitosan (CS)NanocapsulesTo improve the physicochemical stability and solubility of the encapsulated algal oil[@bib130]30*Lactobacillus reuteri*EmulsionTo enhance protection and viability of the encapsulated probiotic bacteria[@bib148]31Lactic acid bacteriaAlginate--pectin gels microcapsulesTo enhance protection and viability of the encapsulated bacteria and thereby enhance nutritional value of the cooked sausages([@bib8])32Inulin and konjac glucomannanEmulsionTo scale up the stability and rheological properties of the emulsions[@bib135]33*Lactobacillus acidophilus* LA-5 as probiotic and hi-maize, inulin, and rice bran as prebioticspectin microparticlesTo enhance protection and viability of the encapsulated bacteria[@bib101]

Interestingly, this technology has shown promising effects not only for the prebiotics but also for probiotics simultaneously. Probiotics derived from a Greek word meaning "for life" and are living organisms which confer potential health benefits including the alleviation of digestive discomfort, reduction of the duration of childhood diarrhea, regulation of intestinal immunity, and improvement of symptoms of the irritable bowel syndrome ([@bib44]). However, to significantly achieve these health benefits associated with probiotics, their protection against processing and storage conditions as well as those encountered during passage through human gut is inevitable. At this point, encapsulation technology has been proven to be effective in protecting probiotics from these adverse conditions, while maintaining their viability and functionality ([@bib101]; M.; [@bib148]). So far a number of different encapsulation based formulations have been implied in food industry to enhance protection and viability of the encapsulated probiotic bacteria and thereby scale up the nutritional value and functional properties of the produced products. The presence of prebiotics in these systems perform several pivotal roles. For example, these prebiotics increase stability of the synthesized systems, aid in developing of novel food products with reduced fats and salt contents and enhance protection and viability of the encapsulated probiotics bacteria. These approaches are of particular importance in the production of novel functional foods the demands for which have increased significantly in recent years. A summary of these formulations developed in recent years with their respective potentials has been given in [Table 1](#tbl1){ref-type="table"}.

2. Conclusions {#sec2}
==============

From the above detailed descriptions, a conclusion can be withdrawn with the facts that DFs and complex resistant undigestible carbohydrates, that withstand digestion by host enzymes in the upper GIT play a pivotal role in driving bacterial fermentation in the large intestine. It could be due to the production of SCFAs from these DFs by the gut microbiota, which in turn paly significant roles in promoting health and well-being. The production of SCFAs mainly depends on dietary substrate, which affects the composition of the bacterial flora, transit time through the colon and luminal pH (which are all interlinked variables). In short, the type of DFs arriving the colon has a remarkable impact on the performance and composition of bacterial communities, thereby influencing the production of SCFAs, the balance of which is vital to maintain gut health. Among all the produced SCFAs, butyrate may be regarded as the most beneficial one for colonic health, which could be due to is principal energy source for the colonycytes as well as its role in modulating cell turnover in the colon. This implies that ensuring an adequate supply of DFs, such that to maintain raised butyrate levels is throughout the entire length of the large intestine, can be a beneficial strategy in the prevention of colon cancer, usually originated in the distal colon. However, interestingly maintaining an optimal levels of all the three SCFAs may have a broader range of health benefits including impacting the progressions of metabolic syndrome such as type 2 diabetes, obesity and CVD. Profound knowledge of particular DFs that develop and stimulate SCFAs particularly butyrate and propionate production, with reducing secondary bile acid conversion and elevating bile acid binding and excretion, would ultimately lead to enhanced defense against both colon cancer and metabolic syndrome. Furthermore, weight loss formulas that are based on lowered carbohydrate and calories intake should maintain ample amounts of DFs to sustain gut health. In addition, being prebiotics and as a food for probiotics, DFs play inevitable role in the development of novel functional foods and hence various formulations have been focused tremendously in recent years. These pre and probiotics-based formulations are aimed to enhance stability of the synthesized systems, protect the encapsulants and promote viability and functionality of the encapsulated probiotics. Therefore, it is strongly recommended that future work is needed to; i) develop novel pre & probiotic based formulations with promising characteristics, ii) evaluate the in vivo efficacy as well as dosage optimization of the designed systems in animal models and iii) carry out clinical trials to find out the significance of these formulations in human subjects suffering from different pathologies.
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